Item 2.02 Results of Operations and Financial Condition. On March 26, 2026 Arcadia Biosciences, Inc. (the “Company”) issued a press release announcing financial results for the fourth quarter and year ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1, and the Company's annual financial information tables are furnished as Exhibit 99.2, to this Current Report on Form 8-K and are incorporated herein by reference. The information furnished in this Form 8-K, the press release attached as Exhibit 99.1, and the financial information attached as Exhibit 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02, in the press release attached as Exhibit 99.1, and in the financial information attached as Exhibit 99.2, shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
RKDA Arcadia Biosciences, Inc. - 8-K
Accession
0001193125-26-1262202.029.01
Item 2.02 - Results of Operations and Financial Condition
Earnings press release item. The actual results are typically in Exhibit 99.1 - fetch may not have completed.
Item 9.01 - Financial Statements and Exhibits
45 words
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Arcadia Biosciences Announces Fourth-Quarter and Full Year 2025 Financial Results and Business Highlights 99.2 Arcadia Biosciences Full Year 2025 Financial Information 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)